Xia Wu

Dr. Xia Wu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in International Immunopharmacology
Verified
Journal Article
Closed access
QWQiaohong Wang
Qiaohong Wang
JGJingze Gao
Jingze Gao
XWXia Wu
Xia Wu

1 May 2017 in International Immunopharmacology
Verified
Journal Article
Closed access
QWQiaohong Wang
Qiaohong Wang
XWXia Wu
Xia Wu

1 November 2017 in International Immunopharmacology
Verified
Journal Article
Closed access
QWQiaohong Wang
Qiaohong Wang
WLWeihua Lou
Weihua Lou
WDWen Di
Wen Di
XWXia Wu
Xia Wu

28 April 2020 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
QWQiaohong Wang
Qiaohong Wang
JGJingze Gao
Jingze Gao
WDWen Di
Wen Di
XWXia Wu
Xia Wu

21 April 2022 in Pharmacological Research
Verified
Journal Article
Closed access
MTMengyu Tao
Mengyu Tao
FSFan Sun
Fan Sun
JWJuan Wang
Juan Wang
YWYujing Wang
Yujing Wang
HZHongrui Zhu
Hongrui Zhu
XWXia Wu
Xia Wu

26 October 2021 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MTMengyu Tao
Mengyu Tao
XWXia Wu
Xia Wu
Epithelial ovarian cancer (EOC) harbors distinct genetic features such as homologous recombination repair (HRR) deficiency, and therefore may respond to poly ADP-ribose polymerase inhibitors (PARPi). Over the past few years, PARPi have been added to the standard of care for EOC patients in both front-line and recurrent settings. Next-generation sequencing (NGS) genomic analysis provides key information, allowing for the prediction of PARPi response in patients who are PARPi naïve. However, there are indeed some limitations in NGS analyses. A subset of patients can benefit from PARPi, despite the failed detection of the predictive biomarkers such as BRCA1/2 mutations or HRR deficiency. Moreover, in the recurrent setting, the sequencing of initial tumor does not allow for the detection of reversions or secondary mutations restoring proficient HRR and thus leading to PARPi resistance. Therefore, it becomes crucial to better screen patients who will likely benefit from PARPi treatment, especially those with prior receipt of maintenance PARPi therapy. Recently, patient-derived organoids (PDOs) have been regarded as a reliable preclinical platform with clonal heterogeneity and genetic features of original tumors. PDOs are found feasible for functional testing and interrogation of biomarkers for predicting response to PARPi in EOC. Hence, we review the strengths and limitations of various predictive biomarkers and highlight the role of patient-derived ovarian cancer organoids as functional assays in the study of PARPi response. It was found that a combination of NGS and functional assays using PDOs could enhance the efficient screening of EOC patients suitable for PARPi, thus prolonging their survival time.